MIRO-CKD — Balcinrenone + dapagliflozin beat dapagliflozin alone on UACR (2025) — Trial Summary

MIRO-CKD — Balcinrenone + dapagliflozin beat dapagliflozin alone on UACR (2025): Multicenter, randomized, double-blind, active-controlled, dose-finding phase 2b trial at 106 sites in 15 countries comparing balcinrenone 15 mg + dapagliflozin 10 mg, balcinrenone 40 mg + dapagliflozin 10 mg, or dapagli

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.